IO Biotech, Inc. Common Stock
IOBTStock
$0.01−99.66%52W
Market Cap$223,041
P/E—
Div yield—
Beta-0.14
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-108.12%
Price vs S&P 500 (4W)-11.71%
VGM Score11.20
Market Capitalization$223,041
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.60
2.60
2.50
2.50
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IOBTIO Biotech, Inc. Common Stock | — | — | F | $0.01 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
IO Biotech is a clinical-stage biopharmaceutical company developing cancer vaccines using its proprietary T-win technology platform. The company's approach targets multiple immunosuppressive pathways to enhance the immune system's ability to recognize and attack cancer cells. This dual-pathway targeting strategy aims to overcome a key mechanism by which tumors evade immune response.